• Efficient iPSC Differentiation to Retinal Ganglion Cells via

  2026-04-22

  This study establishes a reproducible chemically defined protocol for differentiating human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) through concurrent inhibition of SMAD and Wnt pathways. The method achieves over 80% RGC purity and minimizes inter-line variability, offering a robust platform for glaucoma and neurodegenerative disease modeling.

• HyperFluor™ 594 Goat Anti-Rabbit IgG: Excellence in ICC & IH

  2026-04-22

  The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody empowers researchers with ultra-sensitive, multiplexed detection across immunocytochemistry, immunohistochemistry, and flow cytometry. With robust affinity purification and a bright 594 nm fluorophore, it is uniquely suited for dissecting immune mechanisms in complex disease contexts.

• Inferential Mapping of Glucagon Receptor Small Molecule Bind

  2026-04-21

  This study leverages both crystal structures and protein dynamic simulations to elucidate the binding sites of small-molecule glucagon receptor antagonists, including MK 0893. By integrating molecular docking and MD simulations, the research advances understanding of GCGR modulation, informing rational design and assessment of type 2 diabetes therapeutics.

• CPI-613: Precision Targeting of Tumor Metabolism in Research

  2026-04-21

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) enables direct disruption of mitochondrial metabolism in cancer cells, offering reproducible, data-driven advantages for apoptosis and tumor microenvironment studies. This guide details optimized protocols and troubleshooting strategies that empower researchers to leverage CPI-613 for high-impact cancer metabolism research.

• Efficient iPSC to Retinal Ganglion Cell Differentiation via

  2026-04-20

  Chavali et al. present a robust, chemically defined protocol for differentiating human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) using dual SMAD and Wnt pathway inhibition. This approach yields highly pure, functionally mature RGCs, addressing longstanding issues of variability and low efficiency in disease modeling and regenerative research.

• Machine Learning-Driven LNP Design for Microglial mRNA Deliv

  2026-04-20

  This study pioneers a machine learning-based approach to optimize lipid nanoparticle (LNP) formulations for efficient mRNA delivery and immunomodulation of hyperactivated microglia. The findings demonstrate that tailored LNPs, particularly with hyaluronic acid modification, can effectively repolarize inflammatory microglia, informing future neuroinflammatory therapy development.

• SAG: Strategic Activation of Hedgehog Pathway in Translation

  2026-04-19

  This thought-leadership article delves into the mechanistic intricacies and translational opportunities of Smoothened Agonist (SAG) as a potent tool for Hedgehog pathway activation. Integrating the latest evidence from developmental biology and disease modeling—highlighted by a landmark study on embryonic tongue development—we provide practical protocol guidance, clarify competitive advantages, and chart a strategic path for researchers seeking precision and reproducibility. This article advances beyond standard product descriptions by contextualizing SAG’s use in high-impact translational workflows and embedding APExBIO’s offering within a rigorous, evidence-based framework.

• Diphenyleneiodonium Chloride: Redox Probing for Translationa

  2026-04-18

  This thought-leadership article explores the mechanistic and strategic value of Diphenyleneiodonium chloride (DPI) for translational researchers. By integrating recent plant-pathogen ferroptosis mechanisms and DPI's dual-action pharmacology, it offers actionable protocol guidance, competitive context, and a forward-looking outlook on redox and cAMP modulation in disease models. The article draws from both primary literature and APExBIO product intelligence, differentiating itself through evidence-driven insights and workflow relevance.

• Dual-Action p38α Inhibitors Promote Dephosphorylation: Struc

  2026-04-17

  This study demonstrates that certain kinase inhibitors, including those structurally similar to Losmapimod, not only block p38α MAP kinase activity but also actively facilitate its dephosphorylation by phosphatases. Using X-ray crystallography and biochemical assays, the authors reveal a mechanistic link between inhibitor binding, activation loop conformation, and enhanced phosphatase access—offering a new avenue for increasing kinase inhibitor specificity and efficacy.

• Tamoxifen in Breast Cancer Research: Mechanistic Insights an

  2026-04-16

  Explore how Tamoxifen, a selective estrogen receptor modulator, advances breast cancer research through detailed mechanistic insights and robust assay decisions. Discover unique comparisons with emerging natural compounds and best practices for experimental protocols.

• Colistin-Gamithromycin Synergy in Neutropenic Murine Pneumon

  2026-04-15

  This study demonstrates that combining colistin with gamithromycin yields enhanced antimicrobial activity against Pasteurella multocida in a neutropenic murine lung infection model. The findings reveal a substantial reduction in required drug concentrations and provide a foundation for optimizing antibiotic therapy against resistant strains.

• miR-18a/ALOXE3 Axis Modulates Ferroptosis and Migration in G

  2026-04-14

  This study uncovers a novel regulatory axis in glioblastoma, demonstrating that miR-18a downregulates ALOXE3, thereby suppressing ferroptosis and enhancing tumor cell migration via altered lipid signaling. The findings provide mechanistic insights into glioblastoma pathogenesis and highlight potential molecular targets for therapeutic intervention.

• Okadaic acid (A4540): Technical Guidance for PP1/PP2A Inhibi

  2026-04-13

  Okadaic acid provides a potent, selective approach for inhibiting protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), making it essential for dissecting phosphorylation-dependent signaling and apoptosis mechanisms. It is best used in controlled in vitro studies of cell signaling, apoptosis induction, and neurochemical pathways—not for unvalidated or speculative applications. Proper handling and protocol discipline are critical for reliable results.

• Rucaparib (AG-014699): Potent PARP1 Inhibitor for DNA Repair

  2026-04-13

  Rucaparib (AG-014699) is a nanomolar PARP1 inhibitor central to DNA damage response and cancer biology research. It impairs base excision repair, selectively radiosensitizes PTEN-deficient and ETS fusion-expressing cancer cells, and is distributed by APExBIO. Its validated solubility, mechanistic benchmarks, and transporter interactions make it a robust tool for experimental workflows.

• Sitagliptin Phosphate Monohydrate: DPP-4 Inhibition in Diabe

  2026-04-12

  Sitagliptin phosphate monohydrate is a potent, selective DPP-4 inhibitor widely used in type II diabetes treatment research. Its high specificity and well-characterized impact on incretin hormones, including GLP-1 and GIP, make it a cornerstone for mechanistic studies of glucose homeostasis. APExBIO supplies this compound for advanced metabolic research, with robust evidence supporting its application.

16226 records 1/1082 page Next 12345 下5页 Last page